Principal Financial Group
KRYS icon

Principal Financial Group’s Krystal Biotech KRYS Stock Holding History

Principal Financial Group’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$63M Buy
169,550
+7,480
+5% +$2.23M 0.03% 451
2026
Q1 		$41.9M Sell
162,070
-3,004
-2% -$799K 0.02% 544
2025
Q4 		$40.7M Buy
165,074
+22,231
+16% +$4.68M 0.02% 530
2025
Q3 		$25.2M Buy
142,843
+1,960
+1% +$293K 0.01% 739
2025
Q2 		$19.4M Buy
140,883
+14,546
+12% +$2.14M 0.01% 860
2025
Q1 		$22.8M Buy
126,337
+2,884
+2% +$485K 0.01% 742
2024
Q4 		$19.3M Buy
123,453
+3,727
+3% +$661K 0.01% 869
2024
Q3 		$21.8M Sell
119,726
-3,743
-3% -$722K 0.01% 789
2024
Q2 		$22.7M Buy
123,469
+117,510
+1,972% +$19.7M 0.01% 774
2024
Q1 		$1.06M Buy
5,959
+160
+3% +$22.2K ﹤0.01% 1861
2023
Q4 		$719K Buy
5,799
+31
+0.5% +$3.44K ﹤0.01% 1882
2023
Q3 		$669K Sell
5,768
-125
-2% -$15.3K ﹤0.01% 1898
2023
Q2 		$692K Sell
5,893
-240
-4% -$24.5K ﹤0.01% 1894
2023
Q1 		$491K Buy
6,133
+480
+8% +$37.7K ﹤0.01% 1967
2022
Q4 		$448K Buy
5,653
+264
+5% +$19.6K ﹤0.01% 2005
2022
Q3 		$376K Buy
5,389
+749
+16% +$54.1K ﹤0.01% 2024
2022
Q2 		$305K Buy
+4,640
New +$289K ﹤0.01% 2173
2021
Q4 		– Sell
-4,356
Closed -$227K – 2587
2021
Q3 		$227K Sell
4,356
-704
-14% -$41.7K ﹤0.01% 2396
2021
Q2 		$344K Sell
5,060
-2,523
-33% -$176K ﹤0.01% 2313
2021
Q1 		$585K Buy
7,583
+13
+0.2% +$945 ﹤0.01% 2115
2020
Q4 		$454K Buy
+7,570
New +$378K ﹤0.01% 2136

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Principal Financial Group's KRYS Position: Q2 2026 in Review

Principal Financial Group increased its Krystal Biotech (KRYS) stake by 4.6% in Q2 2026, buying an estimated $2.23M and bringing the position to 169,550 shares worth $63M. The position accounts for 0.03% of the portfolio, ranked #451.

Principal Financial Group first reported a position in KRYS in Q4 2020 and has held it in 21 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Principal Financial Group held 169,550 shares of Krystal Biotech worth $63M as of Q2 2026.
  • Principal Financial Group bought 7,480 Krystal Biotech shares in Q2 2026, an estimated $2.23M.
  • Krystal Biotech made up 0.03% of Principal Financial Group's portfolio in Q2 2026, its #451 holding.
  • Principal Financial Group first reported a position in Krystal Biotech in Q4 2020 and has held it in 21 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.